Pemilihan Sclerosing Agent untuk Mencegah Berulangnya Efusi Pleura Masif

Oleh :

dr.Antonius Sarwono Sandi Agus Sp.BTKV, FIHA, MH, FICS.

Pemilihan sclerosing agent untuk mencegah berulangnya efusi pleura masif sampai saat ini belum ada yang dapat dianggap sebagai agent yang paling utama dan unggul. Sclerosing agent yang tersedia saat ini masih memunculkan efek samping berupa aktivitas inflamasi, sehingga pemilihan baru selalu dikaitkan dengan faktor agen yang mudah tersedia dan efisien. Akan tetapi, diyakini bahwa sclerosing agent yang ideal harus menghasilkan adhesi intrapleura yang tahan lama, dengan sesedikit mungkin atau bahkan tanpa peradangan.[1,2]

Efusi Pleura Masif

Efusi pleura masif adalah akumulasi cairan berlebih yang mengisi ruang antara pleura viseral dan pleura parietal. Cairan efusi sering mengandung sel-sel keganasan, karena efusi pleura masif umumnya disebabkan oleh proses inflamasi yang dipicu keganasan. Sejumlah keganasan yang dapat mengakibatkan efusi pleura adalah kanker paru, kanker payudara, kanker ginekologis seperti kanker serviks, limfoma, dan yang tersering mesothelioma.[2]

(Konten ini khusus untuk dokter. Registrasi untuk baca selengkapnya)

Referensi

1. Rodriguez-Panadero F, Montes-Worboys A. Mechanisms of pleurodesis. Respiration. 2012;83:91–98.
2. Neeraj R, Diagnosis and management of malignant pleural effusions : state of the art in 2017, Journal of Thoracic Disease vol 9, suppl 10, September 2017
3. Shojaee S, Voelkel N, Farkas L, et al. Transforming growth factor-beta1 rise in pleural fluid after tunneled pleural catheter placement: pilot study. J Bronchology Interv Pulmonol 2013;20:304-8.
4. Michal M, Clinical Pleurodesis – a review of mechanisms involved in pleural space obliteration. Respir Res. 2019; 20:247.
5. Shaikhrezai K, Thompson AI, Parkin C, et al. Video-assisted thoracoscopic surgery management of spontaneous pneumothorax — long-term results. Eur J Cardiothorac Surg. 2011;40:120–123.
6. Genofre EH, Marchi E, Vargas FS. Inflammation and clinical repercussions of pleurodesis induced by intrapleural talc administration. Clinics. 2007;62:627–634.
7. Tabatabaei SA, Hashemi SM, Kamali A. Silver nitrate versus tetracycline in pleurodesis for malignant pleural effusions; a prospective randomized trial. Adv Biomed Res. 2015;4:178.
8. Balassoulis G, Sichletidis L, Spyratos D, et al. Efficacy and safety of erythromycin as sclerosing agent in patients with recurrent malignant pleural effusion. Am J Clin Oncol. 2008;31:384–389.
9. Chen JS, Chan WK, Yang PC, et al. Intrapleural minocycline pleurodesis for the treatment of primary spontaneous pneumothorax. Curr Opin Pulm Med. 2014;20:371–376.
10. Bucknor A, Harrison-Phipps K, Davies T, et al. Is silver nitrate an effective means of pleurodesis? Interact Cardiovasc Thorac Surg. 2015;21:521–525.
11. Kishi K, Homma S, Sakamoto S, et al. Efficacious pleurodesis with OK-432 and doxorubicin against malignant pleural effusions. Eur Respir J. 2004;24:263–266.
12. Barbetakis N, Antoniadis T, Tsilikas C. Results of chemical pleurodesis with mitoxantrone in malignant pleural effusion from breast cancer. World J Surg Oncol. 2004;2:16. doi: 10.1186/1477-7819-2-16
13. Rahman NM, Davies HE, Salzberg M, et al. Use of lipoteichoic acid-T for pleurodesis in malignant pleural effusion: a phase I toxicity and dose-escalation study. Lancet Oncol. 2008;9:946–952.
14. Antony VB, Nasreen N, Mohammed KA, et al. Talc pleurodesis: basic fibroblast growth factor mediates pleural fibrosis. Chest. 2004;126:1522–1528.
15. Schwarz Y, Star A. Role of talc modulation on cytokine activation in cancer patients undergoing pleurodesis. Pulm Med. 2012;2012:806183.
16. Nasreen N, Mohammed KA, Brown S, et al. Talc mediates angiostasis in malignant pleural effusions via endostatin induction. Eur Respir J. 2007;29:761–769.
17. Montes JF, Garcia-Valero J, Ferrer J. Evidence of innervation in talc-induced pleural adhesions. Chest. 2006;130:702–709.
18. Lansley SM, Varano Della Vergiliana JF, Cleaver AL, et al. A commercially available preparation of Staphylococcus aureus bio-products potently inhibits tumour growth in a murine model of mesothelioma. Respirology. 2014;19:1025–1033.
19. Ren S, Terman DS, Bohach G, et al. Intrapleural staphylococcal superantigen induces resolution of malignant pleural effusions and a survival benefit in non-small cell lung cancer. Chest. 2004;126:1529–1539.
20. Karandashova Sophia, Florova Galina, Azghani Ali O., Komissarov Andrey A., Koenig Kathy, Tucker Torry A., Allen Timothy C., Stewart Kris, Tvinnereim Amy, Idell Steven. Intrapleural Adenoviral Delivery of Human Plasminogen Activator Inhibitor–1 Exacerbates Tetracycline-Induced Pleural Injury in Rabbits. American Journal of Respiratory Cell and Molecular Biology. 2013;48(1):44–52.
21. Tucker TA, Ann Jeffers A, Alvarez A, et al. Plasminogen activator inhibitor-1 deficiency augments visceral mesothelial organization, intrapleural coagulation, and lung restriction in mice with carbon black/bleomycin–induced pleural injury. Am J Respir Cell Mol Biol. 2014;50:316–327.
22. Agarwal R, Khan A, Aggarwal AN, et al. Efficacy & safety of iodopovidone pleurodesis: a systematic review & meta-analysis. Indian J Med Res. 2012;135:297–304.
23. Guo Y, Tang K, Bilaceroglu S, et al. Iodopovidone is as effective as doxycycline in producing pleurodesis in rabbits. Respirology. 2010;15:119–125.
24. Teixeira LR, Vargas FS, Puka J, et al. Effectiveness and safety of iodopovidone in an experimental pleurodesis model. Clinics (Sao Paulo) 2013;68:557–562.
25. Clive AO. Jones HE. Bhatnagar R. et al. Interventions for the management of malignant pleural effusions: a network meta‐analysis. Cochrane Systematic Review–Intervention.2016. https://doi.org/10.1002/14651858.CD010529.pub2
26. Mohsen TA. Zeid AA. Meshref M. et al. Local iodine pleurodesis versus thoracoscopic talc insufflation in recurrent malignant pleural effusion: a prospective randomized control trial. Eur J Cardiothorac Surg. 2011 Aug;40(2):282-6. doi: 10.1016/j.ejcts.2010.09.005.
27. Ali M, Surani S. Pleurodesis. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. https://www.ncbi.nlm.nih.gov/books/NBK560685/
28. Campion E, Mallah SI, Azhar M, O’Keeffe D, Hameed A. A multidirectional two-tube method for chemical pleurodesis could improve distribution of the sclerosing agent within the pleural cavity – A pilot study. Annals of Medicine and Surgery. 2021 Aug;68:102697.
29. Saleh, M.E., Awad, G. & Sanad, M. Chemical pleurodesis for malignant pleural effusion: which agent is perfect?. Cardiothorac Surg 28, 12 (2020). https://doi.org/10.1186/s43057-020-00022-3
30. Cho SJ, Kim SW, Chang JW. Acute pneumonitis consequent on pleurodesis with Viscum album extract: severe chest images but benign clinical course. Multidiscip Respir Med. 2014 Nov 27;9(1):61. doi: 10.1186/2049-6958-9-61. PMID: 25699179; PMCID: PMC4333894.
31. Mierzejewski, M., Korczynski, P., Krenke, R. et al. Chemical pleurodesis – a review of mechanisms involved in pleural space obliteration. Respir Res 20, 247 (2019). https://doi.org/10.1186/s12931-019-1204-x

Masuk atau Daftar

Nomor Ponsel Sudah Terdaftar

Masuk dengan Email

Masuk dengan Email

Masuk dengan Facebook

Masuk atau Daftar

Referensi

Artikel Terkait